UK markets close in 8 hours 19 minutes

Celadon Pharmaceuticals Plc (CEL.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
101.500.00 (0.00%)
As of 03:12PM BST. Market open.
Currency in GBp

Valuation measures4

Market cap (intra-day) 65.17M
Enterprise value 68.71M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.56k
Price/book (mrq)18.61
Enterprise value/revenue 3.27k
Enterprise value/EBITDA -15.02

Trading information

Stock price history

Beta (5Y monthly) 0.04
52-week change 3-27.50%
S&P500 52-week change 325.59%
52-week high 3180.00
52-week low 30.00
50-day moving average 398.27
200-day moving average 3110.50

Share statistics

Avg vol (3-month) 348.16k
Avg vol (10-day) 334.79k
Shares outstanding 564.21M
Implied shares outstanding 664.21M
Float 822.66M
% held by insiders 166.14%
% held by institutions 15.50%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-45,100.00%

Management effectiveness

Return on assets (ttm)-35.60%
Return on equity (ttm)-122.33%

Income statement

Revenue (ttm)21k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-27.30%
Gross profit (ttm)N/A
EBITDA -6.96M
Net income avi to common (ttm)-7.96M
Diluted EPS (ttm)-0.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.61M
Total cash per share (mrq)0.03
Total debt (mrq)4.65M
Total debt/equity (mrq)153.26%
Current ratio (mrq)1.86
Book value per share (mrq)0.05

Cash flow statement

Operating cash flow (ttm)-6.08M
Levered free cash flow (ttm)-4.86M